Johan Oslob MS, PhD

Johan Oslob, Ph.D., serves as a scientific senior director at Bristol Myers Squibb’s Brisbane, CA, the site where the focus is to find new and improved approaches to treat mechanistically-defined subsets of heart disease. In his role, Johan leads a team of researchers that discovers small molecules that modulate disease-causing pathways through novel interactions. Working cross-functionally, Johan’s team uses these small-molecule modulators for preclinical validation as well as starting points for chemical optimization to obtain refined molecules with properties that may be suitable for medicine.

Johan joined Bristol Myers Squibb in 2020 by way of MyoKardia, where he was part of the team that built the company’s research platform and discovered new potential heart medicines that are now in clinical trials.

Prior to MyoKardia, Johan was the director of Chemistry at 3-V Biosciences and also held leadership and lab research positions at Ardelyx, Sunesis Pharmaceuticals, and Pharmacopeia.

Johan completed his degrees in organic chemistry (Ph.D. and MS from the Royal Institute of Technology, Stockholm, Sweden) followed by post-doctoral studies in professor Barry Trost’s laboratories at Stanford University.